Network origin in Carole Cassidy first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Peptimmune, Inc.
 Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products.
15
| Extinct | Biotechnology | 15 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Carole Cassidy via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| DANAHER CORPORATION | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Corporate Officer/Principal Director of Finance/CFO | |
Inhibitex LLC
 Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Pharmaceuticals: Major | Director/Board Member General Counsel | |
| MOMENTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Eximias Pharmaceutical Corp.
 Eximias Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Eximias Pharmaceutical Corp. develops pharmaceuticals for treatment of cancer disorders. It offers its services in the mid-Atlantic areas. The company is headquartered in Berwyn, PA. | Pharmaceuticals: Major | Director/Board Member | |
| PHASEBIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| AMICUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Idun Pharmaceuticals, Inc.
 Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Medical Specialties | Director/Board Member | |
| COLUCID PHARMACEUTICALS INC | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| ECHO GLOBAL LOGISTICS, INC. | Trucking | Corporate Officer/Principal | |
ZP Opco, Inc.
 ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Pharmaceuticals: Major | Director/Board Member | |
Cardioxyl Pharmaceuticals LLC
 Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | Pharmaceuticals: Major | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Boston University | College/University | Doctorate Degree Graduate Degree | |
Cardion GmbH
 Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor | |
| ORYZON GENOMICS S.A. | Biotechnology | Director/Board Member | |
| Boston College | College/University | Undergraduate Degree | |
| US Military Academy | College/University | Undergraduate Degree Undergraduate Degree | |
| The Pennsylvania State University | College/University | Undergraduate Degree | |
| Santa Clara University | College/University | Masters Business Admin | |
| University of Tennessee | College/University | Undergraduate Degree Doctorate Degree | |
| GLYCOMIMETICS, INC. | Pharmaceuticals: Major | Chairman | |
| Universidad Complutense de Madrid | College/University | Undergraduate Degree | |
| SUPERNUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman | |
Teva Biopharmaceuticals USA, Inc.
 Teva Biopharmaceuticals USA, Inc. BiotechnologyHealth Technology Teva Biopharmaceuticals USA, Inc. develops and commercializes biological products. It uses albumin-fusion technology to develop and commercialize certain albumin-fusion proteins for therapeutic use. The company was founded by Craig A. Rosen, Steven C. Mayer, Indra Sanyal and Mark A. Rampy in 2005 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member | |
| Universidad Autónoma de Madrid | College/University | Doctorate Degree | |
Excaliard Pharmaceuticals, Inc.
 Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chief Executive Officer | |
| Basel Institute for Immunology | College/University | Corporate Officer/Principal | |
| CLOVIS ONCOLOGY, INC. | Pharmaceuticals: Major | Chairman | |
GlaxoSmithKline AG
 GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a company based in Munchenbuchsee, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| National Center for Biotechnology Information | General Government | Corporate Officer/Principal | |
| Université d'Aix-Marseille | College/University | Doctorate Degree Doctorate Degree | |
Allievex Corp.
 Allievex Corp. Pharmaceuticals: OtherHealth Technology Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA. | Pharmaceuticals: Other | Founder Founder | |
| EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Synlogic Operating Co., Inc.
 Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
| SYNLOGIC, INC. | Biotechnology | Chief Executive Officer | |
Cogen Immune Medicine, Inc.
 Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Repertoire Immune Medicines, Inc.
 Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Executive Officer |
Statistics
International
| United States | 41 |
| Spain | 4 |
| Switzerland | 3 |
| Canada | 2 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 33 |
| Consumer Services | 11 |
| Commercial Services | 3 |
| Retail Trade | 2 |
| Transportation | 2 |
Operational
| Director/Board Member | 94 |
| Corporate Officer/Principal | 52 |
| Chairman | 32 |
| Founder | 27 |
| Independent Dir/Board Member | 25 |
Most connected contacts
| Insiders | |
|---|---|
| Michael Barrett | 49 |
| Luke Evnin | 42 |
| Jose-Carlos Gutiérrez-Ramos | 24 |
| Robert Carpenter | 19 |
| Thomas Mathers | 19 |
| Fredric D. Price | 16 |
| Ben Bronstein | 16 |
| Julie Krop | 12 |
| Louis J. Arcudi | 9 |
| Christine Blumhardt | 9 |
| Bernice Kuca | 9 |
| Uday Patel | 7 |
| Eric H. Zanelli | 7 |
| Dustan Bonnin | 7 |
| Nicolas Mourier | 6 |
- Stock Market
- Insiders
- Carole Cassidy
- Company connections
